FINACEA FOAM (Bayer HealthCare Pharmaceuticals Inc.)
Welcome to the PulseAid listing for the FINACEA FOAM drug offered from Bayer HealthCare Pharmaceuticals Inc.. This Decreased Protein Synthesis [PE],Decreased Sebaceous Gland Activity [PE] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Bayer HealthCare Pharmaceuticals Inc. |
NON-PROPRIETARY NAME: | azelaic acid |
SUBSTANCE NAME: | AZELAIC ACID |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Decreased Protein Synthesis [PE],Decreased Sebaceous Gland Activity [PE] |
ROUTE: | TOPICAL |
DOSAGE FORM: | AEROSOL, FOAM |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 2015-08-03 |
END MARKETING DATE: | 0000-00-00 |
FINACEA FOAM HUMAN PRESCRIPTION DRUG Details:
Item Description | FINACEA FOAM from Bayer HealthCare Pharmaceuticals Inc. |
LABELER NAME: | Bayer HealthCare Pharmaceuticals Inc. |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 0.15(g/g) |
START MARKETING DATE: | 2015-08-03 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 50419-829_7c4a2987-ebe5-403c-b9a1-1bc82334983c |
PRODUCT NDC: | 50419-829 |
APPLICATION NUMBER: | NDA207071 |
Other AZELAIC ACID Pharmaceutical Manufacturers / Labelers: